Coley Pharmaceutical Group to Report Second Quarter Results on August 2, 2007
25 Luglio 2007 - 2:30PM
PR Newswire (US)
WELLESLEY, Mass., July 25 /PRNewswire-FirstCall/ -- Coley
Pharmaceutical Group, Inc. (NASDAQ:COLY), today announced that the
company will host an investor conference call at 4:30 p.m. Eastern
Time on August 2, 2007 to discuss second quarter 2007 financial
results. To access the live audio broadcast or the subsequent
archived recording of the call, please visit the Investor Center
section of the Coley website at http://www.coleypharma.com/. Please
log onto Coley's website several minutes prior to the start of the
call to ensure adequate time for any software download that may be
required. A replay of this webcast will be available through August
16, 2007. Investors may participate in the conference call by
dialing either + 1- 888-680-0878 in the U.S. or + 1-617-213-4855
outside the U.S. and typing in the passcode 33063062. A replay of
this call will be available at + 1-888- 286-8010 (U.S.) or +1-
617-801-6888 (international) using the passcode 73949500 until
August 16, 2007. The webcast is also being distributed through the
Thomson StreetEvents Network to both institutional and individual
investors. Individual investors can listen to the call at
http://www.fulldisclosure.com/ and institutional investors can
access the call via http://www.streetevents.com/. About Coley
Pharmaceutical Group Coley Pharmaceutical Group, Inc. is an
international biopharmaceutical company, headquartered in
Wellesley, Massachusetts, USA, that discovers and develops TLR
Therapeutics(TM), a new class of investigational drug candidates
that direct the human immune system to fight cancers, allergy and
asthma disorders and to enhance the effectiveness of vaccines.
Coley has established a pipeline of TLR Therapeutic product
candidates currently advancing through clinical development with
partners and has additional product candidates in preclinical
development. Coley has product development, research and license
agreements with Pfizer, sanofi-aventis, GlaxoSmithKline, Merck,
Novartis Vaccines and the United States government. For further
information on Coley Pharmaceutical Group please visit
http://www.coleypharma.com/. Safe Harbor Statement Certain
statements in this news release concerning Coley's business are
considered "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Any or all of the
forward-looking statements in this press release may turn out to be
wrong. They can be affected by inaccurate assumptions Coley might
make or by known or unknown risks and uncertainties, including, but
not limited to: the early stage of product development;
uncertainties as to the future success of ongoing and planned
clinical trials; the risk that results from early stage clinical
trials may not be indicative of results in later stage trials; the
unproven safety and efficacy of products under development;
intellectual property rights and litigation; competitive products;
and other risks identified in Coley's filings with the Securities
and Exchange Commission including, but not limited to, Coley's
Annual Report on Form 10-K for the fiscal year ended December 31,
2006. Consequently, no forward-looking statement can be guaranteed,
and actual results may vary materially. Coley undertakes no
obligation to publicly update forward-looking statements, whether
because of new information, future events or otherwise, except as
required by applicable law. DATASOURCE: Coley Pharmaceutical Group,
Inc. CONTACT: Susan Hager, Senior Director, Investor Relations and
Corporate Communications of Coley Pharmaceutical Group, Inc.,
+1-781-431-9079, ; or Karen L. Bergman, +1-650-575-1509,
kbergman@bccpartner, or Michelle Corral, +1-415-794-8662, , both of
BCC Partners for Coley Web site: http://www.coleypharma.com/
Copyright
Grafico Azioni Coley Pharmaceutical Grp. (MM) (NASDAQ:COLY)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Coley Pharmaceutical Grp. (MM) (NASDAQ:COLY)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Coley Pharmaceutical Grp. (MM) (NASDAQ): 0 articoli recenti
Più Coley Pharmaceutical Grp. (MM) Articoli Notizie